On March 25, 2025 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) taking place April 25-30, 2025 in Chicago, Illinois (Press release, Affimed, MAR 25, 2025, View Source [SID1234651415]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Title: Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer
Authors: Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Schütz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko
Session Category and Title: Phase II Clinical Trials 1
Session Date and Time: Tuesday, April 29, 2025, 9:00 AM – 12:00 PM CDT
Location: Poster Section 49
Poster Board Number: 1
Published Abstract Number: CT161
The full abstract will be published online on April 25, 2025.
More details about the programs for the AACR (Free AACR Whitepaper) Annual Meeting 2025 are available online at AACR (Free AACR Whitepaper) Annual Meeting 2025 | Meetings | AACR (Free AACR Whitepaper).
About AFM24
AFM24 is a tetravalent, bispecific ICE that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.